Poppins (previously Mila) develops digital therapeutics for children with neurodevelopmental disorders. Poppins is designed for early treatment and to increase therapeutic continuity for children with specific learning disorders (SLD). After a successful clinical trial and a €8M financing round, Poppins developed a new therapeutic programme in France opened to all families whose child has a SLD.